Skip to main content
XFOR logo

X4 Pharmaceuticals, Inc.

XFORNASDAQHealthcareBiotechnology

$2.59Today:- (-)1Y −11.11%

As of Oct 16, 2026 close

Market cap
$333.55M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.43$4.83
Volume (live)
-
Avg. volume (3M)
1.08M

X4 Pharmaceuticals (XFOR) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), X4 Pharmaceuticals used $85.62M of cash in operating activities and spent $3.00M on capital expenditures. That left free cash flow of −$88.62M.

X4 Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for X4 Pharmaceuticals, Inc. (XFOR) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-79.20-37.45-101.17-93.87-88.70-62.13-52.81-33.28-33.88
Depreciation & Amortization1.280.800.420.511.890.350.670.100.20
Stock Based Compensation4.308.208.695.200.005.430.000.000.00
Change in Working Capital-2.582.680.345.74-1.50-4.06-3.243.143.42
Change in Accounts Receivable0.50-1.070.000.000.000.000.00-1.37-0.06
Change in Inventory-1.66-2.820.000.000.000.000.000.000.00
Change in Accounts Payable-2.98-0.291.233.431.171.03-2.751.310.18
Change in Other Working Capital3.36-0.32-0.892.44-2.66-5.09-0.483.203.31
Other Operating Activities3.36-105.13-4.802.4417.401.077.324.632.39
Net Cash from Operating Activities-85.62-130.90-96.51-77.10-70.91-58.82-48.06-25.42-27.87
Investing Activities
Capital Expenditures-3.00-0.33-0.06-0.10-0.62-1.36-0.170.00-0.04
Acquisitions0.000.000.000.000.000.0026.410.000.00
Purchases of Investments-63.39-57.13-16.820.000.000.000.000.000.00
Sales/Maturities of Investments74.5426.452.000.000.000.000.000.000.00
Other Investing Activities0.0098.000.000.000.000.001.000.000.00
Net Cash from Investing Activities8.1566.99-14.88-0.10-0.62-1.3627.230.00-0.04
Financing Activities
Debt Repayment0.0020.0020.44-0.800.0012.390.48-1.143.28
Common Stock Issued238.530.2960.00122.6376.250.56140.184.47106.05
Common Stock Repurchased0.000.000.00-0.01-2.00-0.280.00-1.13-0.20
Other Financing Activities0.100.298.08-4.810.00-0.280.004.67-7.87
Net Cash from Financing Activities238.6320.2988.52117.2374.2512.39140.666.87101.26
Summary
Effect of Forex Changes on Cash0.21-0.160.10-0.110.090.57-1.79-50.110.41
Net Change in Cash161.38-43.77-22.7839.922.82-47.38118.05-68.6673.76
Cash at Beginning of Period56.48100.25123.0383.1178.97126.188.1376.793.04
Cash at End of Period217.8556.48100.25123.0381.7978.97126.188.1376.79
Free Cash Flow-88.62-131.23-96.57-77.21-71.52-60.18-48.23-25.42-27.91
Supplemental Disclosures
Interest Paid-7.774.603.012.912.10---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About X4 Pharmaceuticals Cash Flow

What is X4 Pharmaceuticals's free cash flow?

X4 Pharmaceuticals had negative free cash flow of $88.62M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$85.62M minus $3.00M of capital expenditures.

How much does X4 Pharmaceuticals spend on capital expenditures?

X4 Pharmaceuticals spent $3.00M on capital expenditures in fiscal 2025, compared with $326.00K a year earlier.

Does X4 Pharmaceuticals pay dividends or buy back shares?

X4 Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition